CBIGi002-A-1

GBA W378G-correction/2890, 2890-iso

General#

Cell Line

hPSCreg Name
CBIGi002-A-1
Alternative name(s)
GBA W378G-correction/2890, 2890-iso
Cell line type Human induced pluripotent stem cell (hiPSC)
Last update 14th April 2022
Notes Isogenic control for CBIGi002-A.
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Clinical Biospecimen Imaging and Genetic (C-BIG) Repository (CBIG)
Derivation country Canada

External Databases

BioSamples SAMEA13204586
CLO CLO_0103795

General Information

* Is the cell line readily obtainable for third parties?
Yes
Research: allowed
Clinical: not allowed
Commercial: not allowed
Subclone of

Donor Information#

General Donor Information

Sex female

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
Parkinson's Disease
The donor is a carrier of a disease-associated mutation.
Synonyms
  • Parkinson Disease
  • Parkinson's disease
  • Parkinson's Disease
Genetic variants
GBA (target)
1q21
NM_000157.4:c.1249T>G+/-
NP_000148.2:p.Trp417Gly+/- (also known as p.Trp378Gly)
Heterozygous

External Databases (Donor)

BioSamples SAMEA13200845

Ethics#

Also have a look at the ethics information for the parental line CBIGi002-A .
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?

hIPSC Derivation#

General

The source cell information can be found in the parental cell line CBIGi002-A.

Reprogramming method

Vector type Non-integrating
Vector Episomal

Vector free reprogramming

Other

Derived under xeno-free conditions
Unknown
Derived under GMP?
Unknown
Available as clinical grade?
Unknown

Culture Conditions#

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
Gentle Cell Dissociation Reagent
Medium mTeSR™ 1

Characterisation#

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR FACS Enzymatic Assay Expression Profiles
NANOG
Yes
POU5F1 (OCT-4)
Yes
SSEA-4
Yes
TRA 1-60
Yes
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro directed differentiation
Marker Expressed
FOXA2
Yes
Mesoderm
Ont Id: UBERON_0000926
In vitro directed differentiation
Marker Expressed
MIXL1
Yes
Ectoderm
Ont Id: UBERON_0000924
Marker Expressed
Pax6
Yes

Microbiology / Virus Screening

Mycoplasma Negative

Genotyping#

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46,XX
Karyotyping method: G-Banding

Other Genotyping (Cell Line)

Genetic Modification#

Genetic modifications not related to a disease
Isogenic modification
1q21
Heterozygous
After CRISP/Cas9 editing, Sanger sequencing confirmed that the wild-type TGG codon replaced the mutant GGG codon, correcting the heterozygous W378G missense mutation in CBIGi002-A.
Repaired